If we have selected the wrong experience for you, please change it above.
When growth opportunities span multiple markets, knowing where to focus and how to start can be the hardest decision. Deloitte drew on expertise across its global network to give our client a clear advantage.
The Challenge
A fast-growing biotech company was preparing for its next phase of expansion across Eastern Europe, the Middle East and Africa.
The opportunities were significant, but determining the best path forward was not straightforward.
Each market held a different combination of regulatory requirements, reimbursement frameworks, competitive dynamics and partnership ecosystems. What would work in one country might not in another.
The company needed a data-driven go-to-market prioritisation strategy to understand where to focus its resources, which markets offered the greatest potential, and how to reduce the risks associated with expansion.
The Solution
- Deloitte brought together expertise from across its global networkto help navigate a highly fragmented regional landscape.
- We gathered data from multiple sources across the region and assessed the market opportunities, regulatory environments, reimbursement frameworks, competitive landscapes and operational considerations.
- The findings were translated into prioritised market clusters and tailored market-entry strategies, providing the company with a structured approach to its expansion.
Successful expansion is not about entering every market. It is about understanding where you can create the greatest value and build a sustainable position for growth. By combining local market insights with a global perspective, we helped the company cut through complexity, prioritise opportunities and build a clear path forward
- Elsa Torchet. Director, Strategy and Business Design
The Impact
The company gained a clearer view of where to invest, where to expand and where to proceed with caution: a focused approach to capturing growth opportunities across the region.
From a market landscape and drug funding assessment across 9 priority countries, the company's international expansion, now spans 30+ countries.
